v3.26.1
Revenues
 9 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues
3. Revenues
The Company’s revenues are generated through the sale of DNA synthesis and protein solutions and NGS applications products.
Contract Balances
The following table summarizes our contract balances:
(in thousands)June 30,
2026		September 30,
2025
Contract assets(1)
$6,186 $3,857 
Contract liabilities - current (2)
6,466 6,884 
Contract liabilities - non current (2)
5,668 — 
(1) Consists of unbilled amounts primarily related to contracts where the Company has satisfied the performance obligations, but do not yet have the right to bill for.
(2) Consists of receipt of advance payments before the Company's performance obligations related to revenue contracts are met.
For the three and nine months ended June 30, 2026, the Company recognized revenues of $2.9 million and $4.1 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period. For the three and nine months ended June 30, 2025, the Company recognized revenues of $1.7 million and $1.4 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period.
In addition, for all periods presented, there were no revenues recognized in a reporting period from performance obligations satisfied in previous periods. The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of June 30, 2026 was $21.9 million. The Company expects to recognize revenues of $16.3 million over the next twelve months relating to performance obligations unsatisfied as of June 30, 2026.
Disaggregation of Revenues

The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC primarily consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan.

Three months ended June 30, Nine months ended June 30,
(in thousands)2026202520262025
Americas$77,259 $59,387 $199,947 $168,285 
EMEA33,62230,742109,33489,688
APAC7,4955,92823,50819,590
Total$118,376 $96,057 $332,789 $277,563 
The table below sets forth revenues by products. The Company previously reported revenues by product categories: synthetic genes, oligo pools and DNA libraries (collectively, synthetic biology), antibody discovery, and NGS tools. As customers increasingly leverage both synthetic biology tools and biopharma services for antibody discovery together to accelerate discovery and identify breakthrough therapeutics, beginning fiscal 2026, the Company combined synthetic genes, oligo pools, DNA libraries, and biopharma services for antibody discovery into DNA synthesis and protein solutions. Additionally, NGS tools were renamed NGS applications to better reflect their role in DNA sequencing workflows.
Three months ended June 30, Nine months ended June 30,
(in thousands)2026202520262025
DNA synthesis and protein solutions$56,571 $40,773 $160,905 $122,491 
NGS applications61,80555,284171,884155,072
Total$118,376 $96,057 $332,789 $277,563 

The table below sets forth revenues by industry. The Company historically reported revenues by industrial chemicals/materials, academic research, healthcare, and food/agriculture. Beginning fiscal 2026, the Company will disclose revenues by therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners. These updated categories better align with the Company's operations and increase clarity around the Company's key customer groups.

Three months ended June 30, Nine months ended June 30,
(in thousands)2026202520262025
Therapeutics$40,413 $27,048 $118,404 $80,070 
Diagnostics43,84338,134119,118108,647
Industry and applied5,7496,10517,66718,676
Academic research and government15,51211,72440,54536,589
Global supply partners12,85913,04637,05533,581
Total$118,376 $96,057 $332,789 $277,563